Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Free Report) – Research analysts at HC Wainwright boosted their Q2 2026 earnings per share (EPS) estimates for Autolus Therapeutics in a report issued on Monday, August 3rd. HC Wainwright also issued estimates for Autolus Therapeutics’ Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.74) EPS, FY2028 earnings at ($0.83) EPS, FY2029 earnings at ($0.69) EPS and FY2030 earnings at ($0.23) EPS. Get Autolus Therapeutics alerts:Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last announced its earnings results on Friday, May 15th. Get Our Latest Analysis on Autolus TherapeuticsAutolus Therapeutics Price PerformanceShares of Autolus Therapeutics stock opened at $1.95 on Wednesday. Read MoreReceive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.